Comparative Pharmacology
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus LIKMEZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus LIKMEZ.
ELIGLUSTAT TARTRATE vs LIKMEZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eliglustat is a glucosylceramide synthase inhibitor that reduces the biosynthesis of glucocerebroside, a glycolipid that accumulates in Gaucher disease. It acts as a substrate reduction therapy by decreasing the rate of production of glucocerebroside to a level that allows the residual enzyme activity to clear accumulated substrate.
LIKMEZ is a combination of atorvastatin and ezetimibe. Atorvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL receptor expression. Ezetimibe inhibits intestinal cholesterol absorption by blocking the NPC1L1 transporter.
100 mg orally three times daily, at regular intervals (every 8 hours).
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 6.1 to 8.4 hours. In patients with hepatic impairment (Child-Pugh class B or C), half-life may be prolonged (up to 14-22 hours), requiring dose adjustment.
Terminal half-life: 12 hours (range 10-14 h); clinical context: allows once-daily dosing for most patients.
Renal: 41.4% (unchanged drug and metabolites); fecal: 55.4% (mostly as metabolites). Approximately 2% of the dose is excreted unchanged in urine.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor